Tag Archives: forecast
By Pharm Exec | Published: March 12, 2014
Japan’s schizophrenia treatment market value will see revenues doubling from $0.7 billion in 2012 to $1.4 billion by 2022 (a Compound Annual Growth Rate [CAGR] of 7.74%), says a new report from GlobalData.
By Julian Upton | Published: February 4, 2014
The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2 billion in 2012 to $4.2 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.8%, according to a new report from research and consulting firm GlobalData. The company’s latest report states that out of the 10 major […]
By Pharm Exec | Published: January 28, 2014
The gastrointestinal (GI) therapeutics market for Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD) in the Asia-Pacific (APAC) region will increase in value from $564m in 2012 to $784m by 2019 (a CAGR of 4.8%), according to a new report from GBI Research.
By Reflector | Published: January 23, 2014
Pharm Exec’s EU correspondent, Reflector, looks at some of the European regulatory developments earmarked for 2014 and anticipates their effect on the industry. Personnel Some of the big influences on the pharma industry in Europe next year — and for several years to come — will be the big changes upcoming in key personnel in […]
By Julian Upton | Published: January 21, 2014
While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for the 2014 Industry Outlook, Reenita Das, Partner at Frost & Sullivan, says its now more important than […]